QURE

Uniqure NV

QURE, USA

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

https://www.uniqure.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
QURE
stock
QURE

Stifel Maintains uniQure N.V. (QURE) Buy Recommendation Nasdaq

Read more →
QURE
stock
QURE

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm NewMediaWire

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$58.7856

Analyst Picks

Strong Buy

9

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-35.20 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.06 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-444.88 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.88

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 92.28% of the total shares of Uniqure NV

1.

RTW INVESTMENTS, LLC

(9.4013%)

since

2025/06/30

2.

EcoR1 Capital, LLC

(7.2703%)

since

2025/06/30

3.

Vestal Point Capital LP

(6.7436%)

since

2025/06/30

4.

venBio Select Advisor LLC

(6.6069%)

since

2025/06/30

5.

Aberdeen Group PLC

(5.0134%)

since

2025/06/30

6.

Jefferies Financial Group Inc

(3.82%)

since

2025/06/30

7.

Nantahala Capital Management, LLC

(3.7397%)

since

2025/06/30

8.

JPMorgan Chase & Co

(3.2947%)

since

2025/06/30

9.

Franklin Resources Inc

(2.9262%)

since

2025/06/30

10.

Sofinnova Ventures

(2.8402%)

since

2025/06/30

11.

abrdn Healthcare Investors

(2.7891%)

since

2025/08/31

12.

Integral Health Asset Management, LLC

(2.4605%)

since

2025/06/30

13.

BlackRock Inc

(2.4307%)

since

2025/06/30

14.

683 Capital Management LLC

(2.342%)

since

2025/06/30

15.

FMR Inc

(2.1586%)

since

2025/06/30

16.

State Street Corp

(2.0829%)

since

2025/06/30

17.

Franklin Biotechnology Discv A(acc)USD

(1.8891%)

since

2025/08/31

18.

Vanguard Group Inc

(1.7728%)

since

2025/06/30

19.

Two Sigma Investments LLC

(1.715%)

since

2025/06/30

20.

Morgan Stanley - Brokerage Accounts

(1.6554%)

since

2025/06/30

21.

Boxer Capital Management, LLC

(1.6394%)

since

2025/06/30

22.

JPMorgan Small Cap Growth A

(1.6084%)

since

2025/07/31

23.

SPDR® S&P Biotech ETF

(1.5279%)

since

2025/08/31

24.

Ameriprise Financial Inc

(1.3887%)

since

2025/06/30

25.

abrdn World Healthcare

(1.3426%)

since

2025/07/31

26.

Macquarie Healthcare I

(1.2871%)

since

2025/07/31

27.

abrdn Life Sciences Investors

(1.2844%)

since

2025/08/31

28.

Franklin Biotechnology Discovery A

(1.0367%)

since

2025/07/31

29.

MEDICAL BioHealth EUR Acc

(1.0104%)

since

2025/06/30

30.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0042%)

since

2025/07/31

31.

Fidelity Select Biotechnology

(0.7563%)

since

2025/07/31

32.

International Biotechnology Ord

(0.7444%)

since

2025/07/31

33.

Columbia Small Cap Value Discv A

(0.713%)

since

2025/07/31

34.

Columbia Small Cap Value Discovery Fund

(0.6935%)

since

2025/06/30

35.

Strategic Advisers Fidelity US TtlStk

(0.6904%)

since

2025/07/31

36.

Fidelity Select Pharmaceuticals Port

(0.6527%)

since

2025/07/31

37.

iShares Biotechnology ETF

(0.5419%)

since

2025/08/31

38.

Fidelity Extended Market Index

(0.5022%)

since

2025/07/31

39.

JPM Thematics Genetic Thrps C2 dist USD

(0.461%)

since

2025/07/31

40.

Schwab US Small-Cap ETFâ„¢

(0.4445%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.9068

Latest Release

Date

2025-09-30

EPS Actual

-1.38

EPS Estimate

-0.91

EPS Difference

-0.47

Surprise Percent

-51.6484%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.